Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C
An Expanded Access Phase 2 Study of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon for 24 Weeks in Subjects Who Have Undergone Liver Transplantation and Who Have Aggressive, Recurrent Hepatitis C Infection
Sponsor: Gilead Sciences
Listed as NCT01779518, this observational or N/A phase trial focuses on Post-transplant Hepatitis C and remains ongoing. Sponsored by Gilead Sciences, it has been updated 7 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Approved For Marketing
-
Jul 2024 — Sep 2024 [monthly]
Approved For Marketing
-
Jan 2021 — Jul 2024 [monthly]
Approved For Marketing
-
Jun 2018 — Jan 2021 [monthly]
Approved For Marketing
-
Apr 2018 — Jun 2018 [monthly]
Approved For Marketing
Phase: NA → None
▶ Show 2 earlier versions
-
Feb 2017 — Apr 2018 [monthly]
Approved For Marketing NA
-
Jan 2017 — Feb 2017 [monthly]
Approved For Marketing NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Gilead Sciences
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.